Considering the patients’ preference of SC over IV trastuzumab [4] and the saving of preparation and administration times, the SC formulation should be considered as a valuable clinical opportunity to improve the efficiency of HER2-positive breast cancer treatment delivery. This evidence concerns the gene ERBB2 and breast cancer.